Regulated cell death (RCD) is essential for successful systemic cancer therapy. Yet, the
engagement of RCD pathways does not inevitably result in cell death. Instead, RCD …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

Cell death by apoptosis and permanent cell cycle arrest by senescence serve as barriers to
the development of cancer. Chemotherapeutic agents not only induce apoptosis, they can …

Accurate control of gene expression is essential for normal development and dysregulation
of transcription underpins cancer onset and progression. Similar to cell cycle regulation …

The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …

Abstract Cyclin-dependent kinase 9 (CDK9) activity is correlated with worse outcomes of
triple-negative breast cancer (TNBC) patients. The heterodimer between CDK9 with cyclin …

Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an
attractive therapeutic target for many cancers, especially for cancers driven by transcriptional …

Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in
clonal proliferation of abnormally differentiated hematopoietic cells. In this review …

Transcriptional deregulation has emerged as a hallmark of several cancer types. In
metastatic castration-resistant prostate cancer, a stage in which systemic androgen …

Oncogenic mutations in gene encoding FLT3 kinase are often detected in acute myeloid
leukaemia (AML) patients, and several potent kinase inhibitors have been developed …